BioNTech (NASDAQ:BNTX) Given a $300.00 Price Target by UBS Group Analysts

BioNTech (NASDAQ:BNTX) has been assigned a $300.00 target price by equities research analysts at UBS Group in a research note issued on Thursday, Borsen Zeitung reports. UBS Group’s price target would indicate a potential downside of 10.04% from the stock’s previous close.

A number of other equities analysts have also issued reports on BNTX. The Goldman Sachs Group set a $433.00 target price on shares of BioNTech in a research report on Thursday. Zacks Investment Research raised shares of BioNTech from a “sell” rating to a “hold” rating in a report on Friday, August 6th. SVB Leerink upped their price target on shares of BioNTech from $159.00 to $293.00 and gave the company a “market perform” rating in a report on Friday, August 13th. Bryan, Garnier & Co raised shares of BioNTech from a “neutral” rating to a “buy” rating in a report on Wednesday, August 11th. Finally, Redburn Partners reissued a “sell” rating and issued a $146.00 price target on shares of BioNTech in a report on Wednesday, June 16th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $239.46.

Shares of BNTX opened at $333.48 on Thursday. The firm has a 50-day moving average price of $343.21 and a 200 day moving average price of $234.02. The firm has a market capitalization of $80.87 billion, a PE ratio of 17.45 and a beta of -1.59. The company has a quick ratio of 2.57, a current ratio of 2.67 and a debt-to-equity ratio of 0.04. BioNTech has a 52-week low of $61.27 and a 52-week high of $464.00.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Sunday, August 8th. The company reported $10.77 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $8.35 by $2.42. The firm had revenue of $5.31 billion during the quarter, compared to analyst estimates of $3.27 billion. BioNTech had a net margin of 52.48% and a return on equity of 159.73%. BioNTech’s revenue was up 12599.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.38) EPS. On average, equities analysts expect that BioNTech will post 37.71 EPS for the current year.

A number of hedge funds have recently bought and sold shares of the business. WealthShield Partners LLC lifted its stake in BioNTech by 14.9% during the second quarter. WealthShield Partners LLC now owns 270 shares of the company’s stock valued at $60,000 after buying an additional 35 shares in the last quarter. Profund Advisors LLC lifted its stake in BioNTech by 2.7% during the second quarter. Profund Advisors LLC now owns 3,242 shares of the company’s stock valued at $726,000 after buying an additional 84 shares in the last quarter. Royal Bank of Canada lifted its stake in BioNTech by 0.8% during the first quarter. Royal Bank of Canada now owns 12,104 shares of the company’s stock valued at $1,321,000 after buying an additional 93 shares in the last quarter. Firestone Capital Management purchased a new stake in BioNTech during the second quarter valued at about $29,000. Finally, Virtus ETF Advisers LLC lifted its position in shares of BioNTech by 2.8% in the first quarter. Virtus ETF Advisers LLC now owns 5,779 shares of the company’s stock worth $631,000 after purchasing an additional 158 shares in the last quarter. 14.49% of the stock is owned by institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors.

Further Reading: Euro STOXX 50 Index

Analyst Recommendations for BioNTech (NASDAQ:BNTX)

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.